These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35688939)

  • 1. A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
    Gbadamosi MO; Shastri VM; Elsayed AH; Ries R; Olabige O; Nguyen NHK; De Jesus A; Wang YC; Dang A; Hirsch BA; Alonzo TA; Gamis A; Meshinchi S; Lamba JK
    Leukemia; 2022 Aug; 36(8):2022-2031. PubMed ID: 35688939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.
    Gbadamosi M; Meshinchi S; Lamba JK
    Future Oncol; 2018 Dec; 14(30):3199-3213. PubMed ID: 30039981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
    Lamba JK; Chauhan L; Shin M; Loken MR; Pollard JA; Wang YC; Ries RE; Aplenc R; Hirsch BA; Raimondi SC; Walter RB; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
    J Clin Oncol; 2017 Aug; 35(23):2674-2682. PubMed ID: 28644774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.
    Rafiee R; Chauhan L; Alonzo TA; Wang YC; Elmasry A; Loken MR; Pollard J; Aplenc R; Raimondi S; Hirsch BA; Bernstein ID; Gamis AS; Meshinchi S; Lamba JK
    Blood Cancer J; 2019 May; 9(6):51. PubMed ID: 31113932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.
    Rosen DB; Harrington KH; Cordeiro JA; Leung LY; Putta S; Lacayo N; Laszlo GS; Gudgeon CJ; Hogge DE; Hawtin RE; Cesano A; Walter RB
    PLoS One; 2013; 8(1):e53518. PubMed ID: 23320091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.
    Mortland L; Alonzo TA; Walter RB; Gerbing RB; Mitra AK; Pollard JA; Loken MR; Hirsch B; Raimondi S; Franklin J; Pounds S; Cao X; Rubnitz JE; Ribeiro RC; Gamis A; Meshinchi S; Lamba JK
    Clin Cancer Res; 2013 Mar; 19(6):1620-7. PubMed ID: 23444229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
    Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
    Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.
    Pollard JA; Alonzo TA; Loken M; Gerbing RB; Ho PA; Bernstein ID; Raimondi SC; Hirsch B; Franklin J; Walter RB; Gamis A; Meshinchi S
    Blood; 2012 Apr; 119(16):3705-11. PubMed ID: 22378848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.
    Takeshita A
    Int J Hematol; 2013 Jun; 97(6):703-16. PubMed ID: 23709007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
    Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia.
    Hibma J; Knight B
    Clin Pharmacokinet; 2019 Mar; 58(3):335-347. PubMed ID: 30062662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
    Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
    J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.
    Xu Q; He S; Yu L
    Front Immunol; 2021; 12():683595. PubMed ID: 34484181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.
    Baron J; Wang ES
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):549-559. PubMed ID: 29787320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.
    Pollard JA; Loken M; Gerbing RB; Raimondi SC; Hirsch BA; Aplenc R; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
    J Clin Oncol; 2016 Mar; 34(7):747-55. PubMed ID: 26786921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No Evidence that
    Castaño-Bonilla T; Barragán E; Sargas C; Sanz A; Algarra L; Herrera-Puente P; García-Boyero R; Barrios M; Martinez-Cuadron D; Rodriguez-Veiga R; Boluda B; Gil C; Serrano-López J; Martínez-López J; Sayas-Lloris MJ; Olave MT; Riaza-Grau R; Castillo TB; Larrayoz MJ; Amigo R; Jiménez-Velasco A; Sánchez J; Ayala R; Blas C; Lainez D; Serrano-López J; Sanz MA; Alonso-Domínguez JM; Montesinos P
    Dis Markers; 2022; 2022():3132941. PubMed ID: 36051360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemtuzumab ozogamicin for acute myeloid leukemia.
    Appelbaum FR; Bernstein ID
    Blood; 2017 Nov; 130(22):2373-2376. PubMed ID: 29021230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic variation in DNA damage response pathway and response to Gemtuzumab Ozogamicin in pediatric AML: a report from the Children's Oncology Group.
    Shastri VM; Chauhan L; Gbadamosi M; Alonzo TA; Wang YC; Aplenc R; Hirsch BA; Kolb EA; Gamis AS; Meshinchi S; Lamba JK
    Clin Cancer Res; 2024 Jan; ():. PubMed ID: 38197878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemtuzumab ozogamicin in acute myeloid leukemia.
    Godwin CD; Gale RP; Walter RB
    Leukemia; 2017 Sep; 31(9):1855-1868. PubMed ID: 28607471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
    Tarlock K; Alonzo TA; Gerbing RB; Raimondi SC; Hirsch BA; Sung L; Pollard JA; Aplenc R; Loken MR; Gamis AS; Meshinchi S
    Clin Cancer Res; 2016 Apr; 22(8):1951-7. PubMed ID: 26644412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.